GRAL GRAIL, Inc.
GRAIL, Inc. (GRAL) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $2.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.6% since its last earnings release on November 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About GRAIL, Inc.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured.
Sector
Healthcare
Industry
Medical Labs & Research
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.